Advances in cancer immunology and immunotherapy

Ελληνική Ογκολογική Ερευνητική Ομάδα
HELLENIC ONCOLOGY RESEARCH GROUP 2002

30-31
October 2015

Royal Olympic Hotel
Athens

Program

Friday, 30 October 2015

08:45-09:00 Welcome

SESSION 1: Cancer immunology

Chairmen: **D. Thanos (GR), O. Tsitsilonis (GR)**

09:00-09:30 Immunoediting: mechanisms of tumor escape — C.N. Baxevanis (GR)

09:30-10:00 Cancer stem cells: their role in cancer recurrence and cancer treatment — A. Klinakis (GR)

10:00-10:30 Inflammation, immunity and cancer: a yin-yang affair — I.S. Pateras (GR)

Keynote lecture (I)

Chairmen: **T. Whiteside (US), O. Tsitsilonis (GR)**

10:30-11:15 Antigen-specific T cells, suppressor cells and survival in melanoma and breast cancer — G. Pawelec (DE)

11:15-11:30 *Coffee break*

SESSION 2: Tumor microenvironment and immune suppression

Chairmen: **G. Pawelec (DE), C.N. Baxevanis (GR)**

11:30-12:00 Immune response regulation in the tumor microenvironment: lessons learned from gene expression profiling studies — D. Bedognetti (QA)

12:00-12:30 Tumor microenvironment: the impact of cancer and stromal cells in its formation — W.H. Fridman (FR)

12:30-13:00 The significant role of immune suppressive cells in tumor development and progression — T. Whiteside (US)

Keynote lecture (II)

Chairmen: **K. Kosmatopoulos (FR), D. Mavroudis (GR)**

13:00-13:45 Personilized vaccines for cancer immunotherapy/immunomonitoring — B. Seliger (DE)

13:45-15:00 *Lunch break*

SESSION 3: The emerging role of immunotherapy in the treatment of cancer

Chairmen: **W.H. Fridman (FR), C. Kalofonos (GR)**

15:00-15:30 The emerging role of immune checkpoint inhibitors — D. Dangaj (CH)

15:30-16:00 Anti-cancer vaccines: promises and obstacles — K. Kosmatopoulos (FR)

16:00-16:30 Immunosenescence and Cancer: Is there an "Immune Risk Profile" in cancer and ageing? — G. Pawelec (DE)

Keynote lecture (III)
Chairmen: **E. Kourea (GR), A. Koutsopoulos (GR)**

16:30-17:15 Predictive and prognostic biomarkers for the immune checkpoint inhibitors — J.- F. Pouliot

17:15-17:45 *Coffee break*

SESSION 4: Immunotherapy in various tumors (I)
Chairman: **T. Economopoulos (GR)**

17:45-18:00 Immunotherapy in upper GI solid tumors — N. Kentepozidis (GR)

18:00-18:15 Is immunotherapy active in colorectal cancer? — A. Koumarianou (GR)

Keynote lecture (IV)
Chairmen: **V. Georgoulias (GR), A. Kotsakis (GR)**

18:15-19:15 The emerging role of exosomes in immunology of cancer: clinical implication — T. Whiteside (US)

Saturday, 31 October 2015

SESSION 5: Immunotherapy in GU tumors
Chairmen: **A. Bamias (GR), C. Panopoulos (GR)**

09:00-09:20 Advances in prostate cancer immunotherapy — C.N. Baxevanis (GR)

09:20-09:40 Updated data for the immunotherapy of bladder cancer — K. Koutsoukos (GR)

09:40-10:00 Immunotherapy in renal carcinoma — M. Liontos (GR)

SESSION 6: Immunotherapy in Lung cancer
Chairmen: **V. Karavasilis (GR), G. Koumakis (GR)**

10:00-10:20 Targeting immune checkpoints in patients with advanced NSCLC — A. Kotsakis (GR)

10:20-10:40 Is there any role for the vaccines in NSCLC? — K. Kosmatopoulos (FR)

10:40-11:00 Can immunotherapy be used in Small Cell Lung Cancer (SCLC) — A. Charpidou (GR)

11:00-11:30 *Coffee break*

Keynote lecture (V)

Chairmen: **M. Tsiatas (GR), A. Kotsakis (GR)**

11:30-12:15	The role of intestinal bacterial microenvironment in cancer onset and tumor immunotherapy	S. Rafail (US)

Keynote lecture (VI)

Chairmen: **T. Makatsoris (GR), S. Rafail (US)**

12:15-13:00	Chimeric antigen receptor for adoptive immunotherapy of cancer	E. Lanitis (CH)

SESSION 7: Immunotherapy in various tumors (II)

Chairmen: **Ch. Papadimitriou (GR), G. Samonis (GR)**

13:00-13:30	Immune checkpoint inhibitor therapy for lymphomas	K. Stamatopoulos (GR)
13:30-13:45	Immunotherapeutic approaches in the treatment of breast cancer	D. Tryfonopoulos (GR)
13:45-14:00	Is there any role of immunotherapy in the treatment of gynecological malignancies?	I. Syrios (GR)
14:00-14:15	The emerging role of immunotherapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN)	A. Argiris (GR)
14:15-15:30	*Lunch break*	

SESSION 8: Immunotherapy in melanoma

Chairmen: **B. Seliger (DE), N. Kentepozidis (GR)**

15:30-15:50	Clinical update: Targeting immune checkpoints in patients with advanced melanoma	H. Linardou (GR)
15:50-16:10	Combination immunotherapy to enhance efficacy of tumor targeting antibodies	I. Metaxas (CH)
16:10-16:30	Oncolytic viruses: emerging multi-functional approach for the treatment of melanoma	O. Tsitsilonis (GR)
16:30-16:50	Treatment algorithm of Melanoma in the sunrise of 2016	D. Bafaloukos (GR)

Keynote lecture (VII)

Chairmen: **G. Fountzilas (GR), C.N. Baxevanis (GR)**

16:50-17:30	Genetic drivers of immune responsiveness: toward a personalized cancer immunotherapy	D. Bedognetti (QA)
17:30-17:50	*Coffee break*	

SESSION 9: Immuno-Oncology clinical studies

Chairmen: **A. Psyrri (GR), J. Mountzios (GR)**

17:50-18:10	Combination of immune checkpoint inhibitors with targeted treatment	N. Karachaliou (ES)
18:10-18:30	Radio-immunotherapy in cancer patients	J. Georgakopoulos (GR)
18:30-18:50	Effective chemo-immunotherapy of cancer: results from clinical trials	M. Tsiatas (GR)
18:50-19:10	Management of Immune related toxicities and evaluation of immune related response	A. Boutis (GR)

Keynote lecture (VIII)

Chairmen: **T. Whiteside (US), V. Georgoulias (GR)**

19:10-19:50	Wrap up: Immunotherapy from the present to the future	M. Mahjoubi (US)
19:50-20:00	Closing remarks	

Info

Date
30-31 October 2015

Website
http://www.scep.gr/events/event/advances-in-immunology-and-immunotherapy/

Symposium Venue
Royal Olympic Hotel
28-34 Athanasiou Diakou Str.
117 43, Athens, GREECE
Tel.: +30 210 92.88.400
Fax.: +30 210 92.33.317
E-mail: info@royalolympic.com

Official Language
The official language of the Symposium is English.

Certificate of Attendance
The certificate of attendance will be given to the participants at the end of the event.

Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program. The number of credits of Continuing Medical Education (CME-CPD) to be administered to the participants will be calculated on the basis of monitoring time.

The event has been awarded by
Panhellenic Medical Association (PIS) with 12 CME – CPD credits.

Gold sponsor

Bristol-Myers Squibb

Silver sponsors

NOVARTIS ONCOLOGY

Roche

Bronze sponsors

MSD

Pfizer Oncology

Sponsors

AMGEN Oncology

astellas Leading Light for Life

AstraZeneca

LET'S WORK ONCOLOGY FROM BOEHRINGER INGELHEIM

Boehringer Ingelheim

DEMO

ΕΝΟΡΑΣΙΣ

GENESIS pharma

GILEAD Advancing Therapeutics. Improving Lives.

Lilly PHARMASERVE

Merck Serono

MERCK Living Innovation

Pierre Fabre Farmaka S.A.